---
title: Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants
  with glycogen storage disease 1b
date: '2024-05-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38733639/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240512181047&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Empagliflozin has been successfully repurposed for treating neutropenia
  and neutrophil dysfunction in patients with glycogen storage disease type 1b (GSD
  1b), however, data in infants are missing. We report on efficacy and safety of empagliflozin
  in infants with GSD 1b. This is an international retrospective case series on 21
  GSD 1b infants treated with empagliflozin (total treatment time 20.6 years). Before
  starting empagliflozin (at a median age of 8.1 months with a median dose of ...
disable_comments: true
---
Empagliflozin has been successfully repurposed for treating neutropenia and neutrophil dysfunction in patients with glycogen storage disease type 1b (GSD 1b), however, data in infants are missing. We report on efficacy and safety of empagliflozin in infants with GSD 1b. This is an international retrospective case series on 21 GSD 1b infants treated with empagliflozin (total treatment time 20.6 years). Before starting empagliflozin (at a median age of 8.1 months with a median dose of ...